for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ironwood Pharmaceuticals, Inc.

IRWD.OQ

Latest Trade

10.99USD

Change

0.07(+0.64%)

Volume

864,586

Today's Range

10.81

 - 

11.26

52 Week Range

8.79

 - 

14.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.92
Open
10.81
Volume
864,586
3M AVG Volume
45.19
Today's High
11.26
Today's Low
10.81
52 Week High
14.27
52 Week Low
8.79
Shares Out (MIL)
163.65
Market Cap (MIL)
1,787.06
Forward P/E
8.64
Dividend (Yield %)
--

Next Event

Q4 2021 Ironwood Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ironwood Pharmaceuticals Provides Update On FY 2021 Financial Guidance And Announces FY 2022 Financial Guidance

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results And Provides Corporate Development Update

Ironwood Pharmaceuticals Reports FDA Approval Of Revised Linzess Label

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.

Industry

Biotechnology & Drugs

Contact Info

100 Summer St Ste 2300

BOSTON, MA

02110-2156

United States

+1.617.6217722

http://www.ironwoodpharma.com/

Executive Leadership

Julie H. Mchugh

Executive Chairman of the Board

Thomas A. McCourt

President, Chief Executive Officer, Director

Sravan K. Emany

Chief Financial Officer, Senior Vice President

Jason Rickard

Chief Operating Officer, Senior Vice President

John Minardo

Senior Vice President, Chief Legal Officer

Key Stats

2.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.3K

2019

0.4K

2020

0.4K

2021(E)

0.4K
EPS (USD)

2018

-0.950

2019

0.550

2020

0.790

2021(E)

1.243
Price To Earnings (TTM)
3.37
Price To Sales (TTM)
4.32
Price To Book (MRQ)
3.08
Price To Cash Flow (TTM)
3.36
Total Debt To Equity (MRQ)
77.26
LT Debt To Equity (MRQ)
57.46
Return on Investment (TTM)
76.13
Return on Equity (TTM)
67.48

Latest News

Latest News

UPDATE 1-Ironwood appoints Sarissa's Denner to board; shares surge

Ironwood Pharmaceuticals on Friday handed a board seat to Sarissa Capital Management, sparking its shares to surge as much as 14% when the activist investor secured the spot after a quiet but forceful 2-1/2-year campaign to join the group.

Ironwood to cut 100 jobs after acid reflux drug fails study

Ironwood Pharmaceuticals Inc <IRWD.O> said on Tuesday it will cut about 100 jobs after its therapy to treat digestive disorder refractory gastroesophageal reflux failed to significantly reduce heartburn severity in a late-stage trial.

Ironwood Pharma's digestive disease drug fails late-stage study

Ironwood Pharmaceuticals Inc said on Tuesday its therapy to treat refractory gastroesophageal reflux disease failed to significantly reduce heartburn severity in a late-stage trial.

BRIEF-Ironwood, Abbvie Report MD-7246 Phase 2 Data In Patients With Abdominal Pain Associated With IBS-D

* IRONWOOD AND ABBVIE REPORT TOP-LINE PHASE II DATA FOR MD-7246 IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D)

BRIEF-Ironwood, Allergan Receive Notices Of Allowance For Patent Applications Covering 72 MCG Dose Of Linzess

* IRONWOOD AND ALLERGAN RECEIVE NOTICES OF ALLOWANCE FOR PATENT APPLICATIONS COVERING 72 MCG DOSE OF LINZESS® (LINACLOTIDE)

BRIEF-Ironwood Pharmaceuticals Provides Update On Impact Of COVID-19

* IRONWOOD PHARMACEUTICALS PROVIDES UPDATE ON IMPACT OF COVID-19

BRIEF-Ironwood Pharma Says Suspending Interactions By Customer-Facing Employees Through March

* IRONWOOD PHARMACEUTICALS - SUSPENDING PERSONAL INTERACTIONS BY CUSTOMER-FACING EMPLOYEES THROUGH AT LEAST MARCH 31 Source text: (https://bit.ly/2xHKXFP) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Announces Publication Of Positive Iw-3718 Phase Iib Data In Gastroenterology

* IRONWOOD PHARMACEUTICALS ANNOUNCES PUBLICATION OF POSITIVE IW-3718 PHASE IIB DATA IN GASTROENTEROLOGY Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Reports Q4 EPS Of $0.30

* IRONWOOD PHARMACEUTICALS REPORTS STRONG FOURTH QUARTER AND FULL YEAR 2019 RESULTS, EXCEEDING FULL YEAR 2019 GUIDANCE; PROVIDES FULL YEAR 2020 GUIDANCE

BRIEF-Ironwood, Allergan Announce Settlement Resolving Linzess (Linaclotide) Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up